Andexxa Blood Clot Risks Lead to FDA Questions Regarding Safety of the Reversal Agent for Xarelto, Eliquis
Xarelto Side Effects More Likely to Result in Death than Warfarin for Afib Patients with Heart Disease: Study
Side Effects of Blood Thinners, Diabetes Drugs Are Leading Causes of ER Visits Due to Medications: Study
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
AFFF Lawsuit Exposure to firefighting foam chemicals may result in an increased risk of cancer for firefighters, military and airport personnel.
Paraquat Parkinson’s Disease Lawsuits Exposure to the toxic herbicide Paraquat has been linked to a risk of Parkinson's disease.
Gardasil HPV Vaccine Lawsuit Side effects of the Gardasil HPV vaccine have been linked to reports of serious and debilitating autoimmune injuries. Lawyers review cases nationwide.
Filing of Joint Xarelto Lawsuits Involving Multiple Parties Will Not Be Allowed After May 20 April 4, 2016 Austin Kirk Add Your Comments The U.S. District Judge presiding over all federal Xarelto lawsuits indicates that the filing of joint complaints involving multiple plaintiffs will no longer be permitted after May 20, indicating that each individual who experienced bleeding problems after using the drug must file a separate complaint in the federal multidistrict litigation (MDL). There are currently more than 4,500 product liability lawsuits pending in the federal court system, which each involve nearly identical allegations that individuals suffered severe or fatal injuries due to side effects of Xarelto, when doctors were unable to control or stop bleeding that developed among users of the novel oral anticoagulant. Since December 2014, the cases have been centralized before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana for coordinated pretrial proceedings, given the similar questions of fact and law. Procedurally, Judge Fallon previously allowed complaints to be filed in the MDL that contained multiple plaintiffs. However, as the litigation enters a new phase, Judge Fallon indicates that it is now appropriate to terminate the joint complaint filing procedure. Learn More About Xarelto Lawsuits Side Effects of Xarelto May Increase Risk of Uncontrollable Bleeding. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Xarelto Lawsuits Side Effects of Xarelto May Increase Risk of Uncontrollable Bleeding. Learn More SEE IF YOU QUALIFY FOR COMPENSATION In a pretrial order (PDF) issued March 22, Judge Fallon indicates that after May 20, all efforts to file a complaint in the MDL will be governed by the Federal Rules of Civil Procedure, and joint complaints will no longer be accepted by the Clerk’s office. The order was issued on the same day as a joint complaint (PDF) was filed on behalf of 10 plaintiffs, which each claim to have suffered Xarelto bleeding injuries. That lawsuit was filed by plaintiffs Sandra Brown, Robert Capps, Bernard Gaus, Jerome Johnson, June Pike, Claude Raye, John Rivers, Arden Runyan, Felton Schley, and Guiseppina Tubbs, which each suffered internal bleeding after ingesting Xarelto. Xarelto Bleeding Problems Xarelto (rivaroxoaban) is a new-generation anticoagulant that was introduced in 2011 as a replacement for Coumadin (warfarin), which has been the go-to anticoagulant treatment for decades. The drug is part of a new class of medications designed to avoid blood clots among individuals at risk for deep vein thrombosis or pulmonary embolism, which have been promoted as easier to use than warfarin. However, since the drugs have hit the market, there have been a large number of reports involving severe and sometimes fatal bleeding problems with Xarelto and other members of this new class, including Pradaxa and Eliquis. Each of the lawsuits involved in the Xarelto MDL raise nearly identical allegations, indicating that users and the medical community were provided inadequate warnings about the problems with uncontrollable bleeding on Xarelto, and the fact that the anticoagulant lacked a safe and effective reversal agent to allow doctors to quickly stop the blood thinning effects of the drug. While all blood thinners carry a risk of bleeding injury, the side effects of warfarin can be quickly reversed with a widely known antidote of bleeding occurs. However, there was no Xarelto reversal agent when the drug was introduced. Plaintiffs allege that the drug makers failed to adequately warn doctors about the lack of an antidote. Similar claims were raised in the litigation over Pradaxa, which was introduced in October 2010, one year before Xarelto hit the market. More than 4,000 Pradaxa lawsuits were ultimately filed by users of that drug who suffered bleeding injuries. Following several years of litigation, the manufacturer of that medication ultimately agreed to pay $650 million in Pradaxa settlements, with an average of about $150,000 per claim. As Xarelto bleeding lawyers continue to review potential cases for individuals prescribed the anticoagulant throughout the United States, the number of complaints has surpassed the number of claims involved in the Pradaxa litigation, as the drug has become more widely used in recent years. Judge Fallon has scheduled a series of early Xarelto bellwether trials in the MDL, which are expected to begin in February 2017 to help the parties gauge how juries may respond to certain evidence and testimony that is likely to be repeated throughout the litigation. While the outcomes of these trials will not be binding on other plaintiffs, they may help the parties negotiate Xarelto settlements that could avoid the need for thousands of individual cases to go before juries nationwide. Tags: Bayer, Bleeding, Blood Thinners, Johnson & Johnson, Pradaxa, Xarelto More Xarelto Lawsuit Stories Andexxa Blood Clot Risks Lead to FDA Questions Regarding Safety of the Reversal Agent for Xarelto, Eliquis November 21, 2024 Xarelto Side Effects More Likely to Result in Death than Warfarin for Afib Patients with Heart Disease: Study September 1, 2022 Side Effects of Blood Thinners, Diabetes Drugs Are Leading Causes of ER Visits Due to Medications: Study October 15, 2021 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermPhoneThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Mediation To Discuss Settling Covidien Hernia Mesh Lawsuits Set for March 31 Through April 4 (Posted: 2 days ago) Parties involved in Covidien hernia mesh lawsuits indicate they are ready to meet with a mediator in a couple weeks to begin potential settlement negotiations. MORE ABOUT: HERNIA MESH LAWSUITCovidien Hernia Mesh Settlement Talks To Get Underway After Parties Select Mediator Next Week (02/19/2025)Discovery Deadlines in Covidien Hernia Mesh Lawsuits Extended by MDL Judge (12/12/2024)Court Appoints Bard Hernia Mesh Settlement Special Masters To Implement “Intensive” Process To Resolve Claims (11/22/2024) Schedule for Hair Relaxer Lawsuit Bellwether Trials Outlined by MDL Judge (Posted: 3 days ago) A federal judge has outlined the schedule for preparing a group of hair relaxer lawsuits for early bellwether trials, which will not go before a jury until at least 2027. MORE ABOUT: HAIR RELAXER LAWSUITSynthetic Braiding Hair Contains Cancer-Causing Chemicals: Consumer Reports (03/05/2025)Hair Relaxer Wrongful Death Lawsuit Links Fatal Endometrial Cancer to Chemical Straightener Use (03/04/2025)Hair Relaxer Lawsuit Settlement Talks Begin With Focus on Finding Mediator, Parties Report (02/11/2025) Breast Cancer Survivors File Lawsuit Over Recalled BioZorb Tissue Marker (Posted: 4 days ago) A BioZorb tissue marker lawsuit representing five women from across the country claims that the recalled implant was defectively designed, resulting in a recall and numerous complications. MORE ABOUT: BIOZORB LAWSUITBioZorb Attorneys Propose Leadership Structure for Lawsuits Over Recalled Tissue Marker (03/05/2025)Schedule Leading to First BioZorb Lawsuit Jury Trial in September 2025 Outlined By Court (02/21/2025)Judge Indicates BioZorb Recall and Warning Letter Do Not Warrant Reopening Discovery in Bellwether Cases (02/12/2025)
Andexxa Blood Clot Risks Lead to FDA Questions Regarding Safety of the Reversal Agent for Xarelto, Eliquis November 21, 2024
Xarelto Side Effects More Likely to Result in Death than Warfarin for Afib Patients with Heart Disease: Study September 1, 2022
Side Effects of Blood Thinners, Diabetes Drugs Are Leading Causes of ER Visits Due to Medications: Study October 15, 2021
Mediation To Discuss Settling Covidien Hernia Mesh Lawsuits Set for March 31 Through April 4 (Posted: 2 days ago) Parties involved in Covidien hernia mesh lawsuits indicate they are ready to meet with a mediator in a couple weeks to begin potential settlement negotiations. MORE ABOUT: HERNIA MESH LAWSUITCovidien Hernia Mesh Settlement Talks To Get Underway After Parties Select Mediator Next Week (02/19/2025)Discovery Deadlines in Covidien Hernia Mesh Lawsuits Extended by MDL Judge (12/12/2024)Court Appoints Bard Hernia Mesh Settlement Special Masters To Implement “Intensive” Process To Resolve Claims (11/22/2024)
Schedule for Hair Relaxer Lawsuit Bellwether Trials Outlined by MDL Judge (Posted: 3 days ago) A federal judge has outlined the schedule for preparing a group of hair relaxer lawsuits for early bellwether trials, which will not go before a jury until at least 2027. MORE ABOUT: HAIR RELAXER LAWSUITSynthetic Braiding Hair Contains Cancer-Causing Chemicals: Consumer Reports (03/05/2025)Hair Relaxer Wrongful Death Lawsuit Links Fatal Endometrial Cancer to Chemical Straightener Use (03/04/2025)Hair Relaxer Lawsuit Settlement Talks Begin With Focus on Finding Mediator, Parties Report (02/11/2025)
Breast Cancer Survivors File Lawsuit Over Recalled BioZorb Tissue Marker (Posted: 4 days ago) A BioZorb tissue marker lawsuit representing five women from across the country claims that the recalled implant was defectively designed, resulting in a recall and numerous complications. MORE ABOUT: BIOZORB LAWSUITBioZorb Attorneys Propose Leadership Structure for Lawsuits Over Recalled Tissue Marker (03/05/2025)Schedule Leading to First BioZorb Lawsuit Jury Trial in September 2025 Outlined By Court (02/21/2025)Judge Indicates BioZorb Recall and Warning Letter Do Not Warrant Reopening Discovery in Bellwether Cases (02/12/2025)